Pawar Dinesh, Chatterjee Abhishek, Epari Sridhar, Sahay Ayushi, Janu Amit, Krishnatry Rahul, Goda Jayant Sastri, Shetty Prakash, Moiyadi Aliasgar, Gupta Tejpal
Department of Radiation Oncology, Advanced Centre for Treatment Research & Education in Cancer (ACTREC)/Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
Department of Pathology, Advanced Centre for Treatment Research & Education in Cancer (ACTREC)/Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
J Clin Neurosci. 2021 Feb;84:91-96. doi: 10.1016/j.jocn.2020.11.051. Epub 2020 Dec 24.
Central neurocytoma is a rare benign brain tumor that typically arises from the subependymal lining of the lateral ventricles in young adults and is generally associated with excellent survival following neurosurgical excision alone. This is a retrospective clinical audit of biopsy-proven neurocytoma registered between 2004 and 2019 at a single institution in India. All time-to event outcomes were analyzed using Kaplan-Meier method and compared with the log-rank test. Any p-value <0.05 was considered statistically significant. A total of 66 patients with neurocytoma were included in the descriptive analysis. Median age of study cohort was 31 years with equitable gender ratio. Majority (83%) of tumors were intraventricular, lateral ventricle being the commonest location. Following maximal safe resection, patients were generally kept on close clinico-radiological surveillance. Most patients (80%) had typical World Health Organization (WHO) grade II neurocytoma with remaining 20% showing histological atypia and/or high-grade features. Outcome analysis was restricted to 35 patients with relevant treatment details and adequate follow-up information. Six patients experienced recurrent/progressive disease with 2 documented deaths. At a median follow up of 52 months, 5-year Kaplan-Meier estimates of progression-free survival and overall survival were 93.3% and 96.8% respectively. Three patients developed delayed recurrence (>5-years after initial diagnosis) underscoring the importance of long-term follow-up. Atypical/high-grade histology was associated with inferior survival that may stand to benefit with upfront adjuvant radiotherapy. This represents the largest single-institution series of central neurocytoma and demonstrates excellent outcomes with adequate surgical resection alone, reserving radiotherapy for large residual tumor, recurrent disease, and/or atypical high-grade histology.
中枢神经细胞瘤是一种罕见的良性脑肿瘤,通常发生于年轻成年人侧脑室的室管膜下,一般单纯经神经外科切除后生存率良好。这是一项对2004年至2019年期间在印度一家机构登记的经活检证实的神经细胞瘤进行的回顾性临床审计。所有事件发生时间结局均采用Kaplan-Meier方法分析,并与对数秩检验进行比较。任何p值<0.05被认为具有统计学意义。共有66例神经细胞瘤患者纳入描述性分析。研究队列的中位年龄为31岁,性别比例均衡。大多数肿瘤(83%)位于脑室内,最常见的部位是侧脑室。在进行最大安全切除后,患者通常接受密切的临床影像学监测。大多数患者(80%)患有典型的世界卫生组织(WHO)II级神经细胞瘤,其余20%表现出组织学异型性和/或高级别特征。结局分析仅限于35例有相关治疗细节和充分随访信息的患者。6例患者出现复发/疾病进展,有2例记录死亡。中位随访52个月时,5年无进展生存率和总生存率的Kaplan-Meier估计分别为93.3%和96.8%。3例患者出现延迟复发(初始诊断后>5年),强调了长期随访的重要性。非典型/高级别组织学与较差的生存率相关,可能从 upfront 辅助放疗中获益。这是最大的单机构中枢神经细胞瘤系列研究,表明单纯充分的手术切除可取得良好结局,仅对大的残留肿瘤、复发疾病和/或非典型高级别组织学保留放疗。